BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.9%

Neg 0% Neu 88.9% Pos 0%

BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $9 price target.

Comments

No comments yet. Be the first!